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Abstract
Background: Recent investigations showed single associations between uric acid levels, functional parameters,
exacerbations and mortality in COPD patients. The aim of this study was to describe the role of uric acid within the
network of multiple relationships between function, exacerbation and comorbidities.
Methods: We used baseline data from the German COPD cohort COSYCONET which were evaluated by standard
multiple regression analyses as well as path analysis to quantify the network of relations between parameters,
particularly uric acid.
Results: Data from 1966 patients were analyzed. Uric acid was significantly associated with reduced FEV1, reduced
6-MWD, higher burden of exacerbations (GOLD criteria) and cardiovascular comorbidities, in addition to risk factors
such as BMI and packyears. These associations remained significant after taking into account their multiple
interdependences. Compared to uric acid levels the diagnosis of hyperuricemia and its medication played a
minor role.
Conclusion: Within the limits of a cross-sectional approach, our results strongly suggest that uric acid is a
biomarker of high impact in COPD and plays a genuine role for relevant outcomes such as physical capacity
and exacerbations. These findings suggest that more attention should be paid to uric acid in the evaluation
of COPD disease status.
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Background
Recent investigations showed an increased mortality in
COPD patients with elevated uric acid (UA) levels [1, 2]
and described UA as an independent predictor of 30-day
mortality of acute exacerbations [2]. UA is known to be
associated with markers of systemic inflammation [3],
bronchoconstriction by stimulation of endothelin-1 [4, 5],
as well as oxygen desaturation [6].Both lower and higher
levels of UA have been described as risk factors for airway
obstruction [7, 8], also in addition to restrictive pattern
linked to UA [9]. Therefor the worse outcome of COPD
patients with hyperuricemia seems to involve a number of
factors including systemic inflammation, oxygen desatur-
ation and lung function alterations. Hyperuricemia is also
associated with an increasing risk of coronary heart dis-
ease [10], a comorbidity that is relevant for mortality in
COPD patients [11]. As an overall marker of functional
capacity in COPD the 6-min walk distance (6-MWD) is
well established and known to be a stronger predictor of
mortality than other markers of severe COPD [12]. In
view of the complexity of the disease and interdependence
of parameters, the functional changes related to uric acid
[2, 13] may well include changes in 6-MWD, in addition
to associations with comorbidities and exacerbations, even
if common risk factors such as age, gender, smoking and
body-mass index (BMI) have been taken into account.
However, the multiple associations between parameters
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may render it difficult to quantify the causal role of UA
and to separate direct and indirect effects from each other.
This can be done using path analysis as a tool to integrate
and cross-check the results of conventional regression
analyses that have been performed for single outcome
measures but never put into a comprehensive picture.
Based on this the aim of this study was to identify the
role of the biomarker UA for spirometric parameters,
6-min walk distance, exacerbation rate and cardiovascu-
lar comorbidities in COPD while taking into account the
fact that these outcome measures are related to each
other. The hypothesis was that UA has direct effects
on these measures that cannot be explained by their
mutual relationships and common risk factors. Such
information could be helpful to understand patho-
physiological mechanisms and the responses to ther-
apy. For this purpose we used data from the German
COPD cohort study COSYCONET (COPD and
Systemic Consequences-Comorbidities Network).
Methods
Study population
The analysis was based on the baseline data set of
COSYCONET, which is a multi-center study with focus
on comorbidities in COPD [14]. Patients were enrolled
in COSYCONET, if the following inclusion criteria were
fulfilled: aged 40 years and older, diagnosis of COPD or
chronic bronchitis, availability for repeated study visits
over at least 18 months and if none of the following ex-
clusion criteria was fulfilled: having undergone major
lung surgery (e.g. lung volume reduction, lung trans-
plant), moderate or severe exacerbation within 4 weeks
prior to the visit, having a lung tumor, physical or cogni-
tive impairment resulting in an inability to walk or to
understand the intention of the project [14].
From n = 2741patients recruited into COSYCONET
only patients with complete data allowing the
categorization into GOLD grades 1–4 and GOLD groups
A-D (2017) [15] based on the COPD Assessment Test
(CAT, threshold 10 according to GOLD recommenda-
tions [15]) were included into this analysis; this required
valid values of forced expiratory volume in 1 s (FEV1),
forced vital capacity (FVC) and CAT. Moreover, valid
data on body-mass index (BMI), packyears of smoking,
6-min walk distance (6-MWD), serum levels of UA and
creatinine, as well as hyperuricemia-related medication
were required. The exacerbation risk for the ABCD
grouping was based on the 12-month history of exacer-
bations of all severities, including hospitalization, as
described by GOLD (with high risk indicated by a
history of two non-hospitalized exacerbations, or one ex-
acerbation leading to hospital admission) [15]. This re-
sulted in a subset of 1966 out of 2741 patients recruited
into COSYCONET [14]. The COSYCONET study had
been approved by the ethical committees of all study
centers, and all patients gave their written informed
consent.
Assessments
The study protocol and panel of assessments have been
described previously [14]. The diagnosis of hyperurice-
mia used for the description of the baseline characteris-
tics of the study cohort was based on patients’ reports of
a doctor-based diagnosis, irrespective of medication. In
the absence of a report, the diagnosis was also assumed
if hyperuricemia-specific medication was identified; de-
tails of this procedure have been given previously [16].
In the statistical analyses we primarily included all pa-
tients, i.e. (a) patients without any diagnosis of hyperuri-
cemia according to these criteria, (b) patients with the
reported diagnosis plus hyperuricemia-specific medica-
tion, and (c) patients with the reported diagnosis but no
hyperuricemia-specific medication. It should be ac-
knowledged that in all analyses the target variable was
UA and not the diagnosis of hyperuricemia. The diagno-
sis was used only in sensitivity analyses in which either
group (b) or (c) were excluded to address of role of diag-
nosis and medication for the associations with UA. In
addition to UA, we included the risk factors age, BMI,
gender, smoking in terms of packyears, the functional
parameters 6-min walk distance (6 MWD), FEV1 and
FVC, each in % predicted, as well as a binary exacerba-
tion category. The categorization of low and high exac-
erbations was based on the GOLD groups A-D
asdefined in GOLD 2017, and we collapsed the A-D
groups into binary subgroups i.e. “low” comprising
groups A and B, and “high” comprising groups C and D
[15]. Predicted values of FEV1 and FVC were taken from
the Global Lung Initiative (GLI) [17]. To quantify the
burden from cardiovascular comorbidities we defined a
cardiovascular comorbidity count (range 0–5) by sum-
ming up the diagnoses of hypertension, coronary artery
disease, myocardial infarction, heart failure and heart
rhythm disorder.
Statistical analysis
Data are presented in the tables as numbers or mean
values and standard deviations (SD). Comparisons be-
tween the three groups (no diagnosis of hyperuricemia,
diagnosis of hyperuricemia and disease-specific medica-
tion, diagnosis of hyperuricemia and no disease-specific
medication) were performed by univariate analysis of
variance (ANOVA), or by chi-square-tests in the case of
categorical variables. The relationships between variables
were assessed using multiple linear regression analysis in
case of continuous outcome variables, and binary logistic
regression analysis for the exacerbation variable. The
distributions of packyears and creatinine were
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right-skewed and therefore transformed to reduce a po-
tential bias in the numerical estimates of associations.
Approximately symmetric distributions were achieved by
taking the square root of the variable “packyears”.
The results demonstrated multiple relationships be-
tween the variables that could only partially be ad-
dressed by conventional regression analysis. There are
statistical methods to describe complex networks and
especially to differentiate between direct and indirect
(i.e. mediated) effects. A common approach is path ana-
lysis [18] which has recently been used in COPD re-
search to deal with such situations [19, 20]. Path analysis
is particularly capable of integrating the results of a
whole set of regression analyses and eliminating
non-causal associations. As the procedure is primarily a
method to exclude models that do not adequately de-
scribe the data [18], the specification of the model typic-
ally requires input from pathophysiological knowledge.
The resulting model represents a specific hypothesis and
is then tested by statistical means. Based on patho-
physiological considerations and the results of the re-
gression analyses we constructed a path analysis model,
integrating the dependence of variables on risk factors
with their dependence on the biomarker UA and then
additionally incorporating the relationship to the exacer-
bation variable. For computation the software package
AMOS (IBM Corp., Armonk, NY, USA) with generalized
least squares estimation (GLS) was used, and the good-
ness of fit was described by the chi-square statistics, the
comparative fit index (CFI) and the root mean square
error of approximation (RMSEA). CFI values ≥0.95 and
RMSEA values ≤0.05 are conventionally as indicating a
good fit. The chi-square statistics describes the deviation
from the model and is therefore acceptable if p ≥ 0.05.
All other statistical analyses were performed by the
package SPSS version 24 (IBM Corp., Armonk, NY,
USA). P-values < 0.05 were considered as statistically
significant.
Results
Description of the study population
The characteristics of the study population stratified ac-
cording to the presence or absence of diagnosis and spe-
cific treatment are given in Table 1, demonstrating that
the levels of uric acid depended on the presence of spe-
cific medication in patients with the diagnosis of hyper-
uricemia. There were significant differences in the serum
concentration of UA between the three groups (p <
0.001, ANOVA). Post-hoc tests revealed pairwise signifi-
cant differences between patients without the diagnosis
of hyperuricemia, those with specific therapy, and those
with diagnosis of HU without specific therapy (p < 0.05
each). This underlines that the diagnosis of hyperurice-
mia is not congruent with elevation of the biomarker
Table 1 Baseline characteristics of the subgroups
Parameter Non-HU HU-specific medication HU-diagnosis w/o
specific medication
P-values
N (%) 1610 (81.9%) 174 (8.6%) 182 (9.3%) –
Gender (m/f) 937/673 154/20 133/49 p < 0.001*
Age (y) 64.2 ± 8.5
[63.8;64.6]
67.7 ± 8.3
[66.7;68.8]
66.3 ± 6.9
[65.3;67.3]
p < 0.001*
BMI (kg/m2) 26.2 ± 5.0
[26.0;26.4]
29.6 ± 5.8
[28.8;30.5]
28.4 ± 5.1
[27.7;29.1]
p < 0.001*
Packyears 47.3 ± 34.8
[45.6;49.0]
53.0 ± 31.8
[48.3;57.8]
61.6 ± 44.5
[55.1;68.1]
p < 0.001*
FEV1%predicted 52.9 ± 18.6
[52.0;53.8]
53.4 ± 17.8
[50.8;56.1]
53.5 ± 16.6
[51.1;55.9]
p = 0.886
FVC%predicted 79.5 ± 18.9
[78.6;80.4]
76.2 ± 18.2
[73.4;78.9]
78.0 ± 18.1
[75.3;80.6]
p = 0.061
6-MWD (m) 420.6 ± 106.4
[415.4;425.8]
394.0 ± 102.2
[378.7;409.3]
401.5 ± 100.3
[386.8;416.2]
p = 0.001*
Uric acid (mg/dl) 5.83 ± 1.60
[5.75;5.91]
6.22 ± 1.43
[6.00;6.43]
7.02 ± 1.78
[6.76;7.28]
p < 0.001*
GOLD 1/2/3/4 151/685/610/164 16/79/65/14 12/84/76/10 p = 0.319
GOLD A/B/C/D 188/859/25/538 15/88/2/69 15/94/5/68 p = 0.312
Exa-cata (low/high) 1047/563 103/71 109/73 p = 0.148
The table shows mean values and standard deviations or absolute numbers, as well as 95% confidence intervals in square brackets. Column 4 shows the p-values
of comparisons between patients without the diagnosis of hyperuricemia, those with a diagnosis plus hyperuricemia-specific medication, and those with a
diagnosis but no hyperuricemia-specific medication (univariate ANOVA or chi-square-tests in the case of categorical variables). Significant (p < 0.05) differences are
marked with (*). aExa-cat indicates the exacerbation category as used in the GOLD 2017 ABCD grouping, i.e. “low” comprising the groups A and B, and “high”
comprising the groups C and D
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uric acid. In addition we stratified UA levels according
to the GOLD A-D groups (Fig. 1). The mean number
(SD) of cardiovascular comorbidities was 0.96 (±0.99).
Relationship between variables
The transformed values of packyears (see methods) were
used for all subsequent analyses. To properly describe
the associations between variables in the presence of
multiple correlations we followed a stepwise approach,
using linear and logistic regression analyses which were
performed using the complete data set (n = 1966).
Dependence of functional parameters on risk factors
First we determined the associations with the risk factors
age, BMI, gender and packyears which were taken as
predictors in multiple linear regression analyses. FEV1%
predicted was dependent on gender, age and BMI (p <
0.05 each); FVC % predicted on age (p = 0.010); 6-MWD
on gender, age and BMI (p < 0.05 each); creatinine on
gender, age, BMI and packyears (p < 0.05 each); and UA
on gender, age, BMI and packyears (p < 0.05 each).
When FEV1% predicted was introduced as an additional
predictor of 6-MWD, this association was also signifi-
cant (p < 0.001). The count of cardiovascular comorbidi-
ties depended on gender, age and BMI (p < 0.001 each)
but not packyears. Moreover, a logistic regression ana-
lysis revealed that the exacerbation category depended,
among risk factors, only on age (p = 0.005).
Associations with uric acid
Second, we determined the associations with UA as pre-
dictor of lung function and physical capacity in linear re-
gression analyses, taking into account the risk factors.
FEV1% predicted and FVC % predicted were dependent
on UA (p ≤ 0.003), as well as 6-MWD on UA (p <
0.001). In addition, the cardiovascular comorbidity count
was associated with UA (p < 0.001), as well as the binary
exacerbation category (p < 0.002; logistic regression ana-
lysis). Gender was significant (p < 0.05 each) in all of
these analyses except for FEV1% predicted.
Exacerbation category versus function and cardiovascular
comorbidities
Third, the association between the binary exacerbation
category and the functional parameters was analysed
using multiple logistic regression, again with gender as
covariate. FEV1% predicted, 6-MWD (p < 0.001 each)
and cardiovascular comorbidities (p = 0.023) were sig-
nificant predictors, whereas FVC % predicted was far
from significance (p = 0.592). The same result was ob-
tained using the cardiovascular comorbidity count as
depended variable (p < 0.001 each).
Integration of results into a path analysis model
The results described above revealed multiple relation-
ships between risk factors, functional variables, exacer-
bations and biomarkers. To delineate this network of
interdependences in greater detail we used the approach
of path analysis.
Fig. 1 Uric acid levels stratified according to GOLD groups A-D based on the COPD Assessment Test (CAT).The figure shows the uric acid levels
for patients without the diagnosis of hyperuricemia, those with a reported diagnosis plus hyperuricemia-specific medication, and those with a
reported diagnosis but no or non-specific medication stratified according to GOLD groups A-D. Number of patients in the different GOLD groups:
A = 218, B = 1041, C = 32, D = 675
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FVC was omitted from these analyses as it was highly
correlated with FEV1, posing a problem due to collinear-
ity. Moreover, the effects of gender were taken into ac-
count by using gender-adjusted values for all variables; the
only exception was the binary exacerbation category for
which no meaningful adjustment could be introduced.
Therefore gender was implicit in the path analyses
and disappeared as an explicit predictor. In designing
the model we used the results of the regression ana-
lyses as well as pathophysiological considerations.
Path analysis model
The final model integrated risk factors, UA, functional
indices, cardiovascular comorbidities and exacerbations
into a comprehensive network that was compatible with
the results of the conventional regression analyses. In a
first step we used the results of the regression analyses
that can be found under “Dependence of functional pa-
rameters on risk factors”. Additionally, we introduced
correlations between the predictors BMI and packyears,
and age and packyears, as these were suggested by the
data. In a second step we used the result given under
“Associations with uric acid”, to describe the additional
relationships between UA, FEV1% predicted and
6-MWD. In the third step we incorporated results for
the binary exacerbation category and the count of car-
diovascular comorbidities as given in “Exacerbation cat-
egory versus function and cardiovascular comorbidities”.
Only associations identified as statistically significant
were kept in the final model. It should be noted, that
even in the presence of multiple other pathways UA had
independent effects on FEV1 (p = 0.005), 6-MWD (p <
0.001) and cardiovascular comorbidity count (p < 0.001),
whereby UA levels were influenced by age, BMI and
packyears. Except for one link (between UA and exacer-
bation category) all relationships identified as statistically
significant in the regression analyses remained signifi-
cant in the comprehensive model. This consistency, to-
gether with the good fit of the data, indicated the
validity of the model which we found. The chi-square
value of fit with generalized least squares estimation was
12.306 with 8 degrees of freedom and a p-value of 0.138,
the corresponding CFI 0.996, and the RMSEA 0.017.
The standardized regression and correlation coefficients
of the final path analysis model are shown in Table 2.
For the purpose of illustration the final model is shown
in two parts, the first describing the relationships to risk
factors (Fig. 2), and the second the relationship between
all other variables except risk factors (Fig. 3). Thus the
final model is the overlay of both figures (see Table 2).
Sensitivity analyses
All analyses described above were performed in the total
population of patients (n = 1966). As indicated in Table 1,
there were significant differences in UA levels between
patients with hyperuricemia with vs without specific
medication. As these groups were too small to be stud-
ied separately in the multivariate analyses we addressed
their influence by excluding these subgroups. First, we
repeated the path analysis for patients without any diag-
nosis of hyperuricemia (n = 1610); the model of Figs. 2
and 3 was fully confirmed. As the presence of specific
medication might affect the associations with UA we
then repeated the path analysis excluding the respective
group, while keeping that without the diagnosis of hy-
peruricemia and that with the diagnosis but without spe-
cific medication who showed elevated levels of UA
(Fig. 1). This resulted in 1792 patients. The path analysis
model of Figs. 2 and 3 was fully confirmed, but a signifi-
cant additional link from UA to exacerbations emerged
(p = 0.028), underlining the importance of UA per se.
This link had been only at the border of statistical sig-
nificance (p = 0.063) when using the whole study
population.
Discussion
Previous studies have indicated a role of uric acid (UA)
for mortality, exacerbations and lung function in COPD
[1, 2]. The results of our cross-sectional analysis are in
line with the different findings and more closely identify
its role within the network of functional parameters, ex-
acerbations, cardiovascular comorbidities and risk fac-
tors. Beyond conventional regression analyses we used
the approach of path analysis to account for both direct
and indirect effects of UA as closely as possible. Higher
levels UA were linked to higher airway obstruction in
terms of FEV1, lower physical capacity in terms of
6-MWD and a greater number of cardiovascular comor-
bidities. Both FEV1 and 6-MWD mediated an indirect
effect of UA on exacerbations as defined by GOLD 2017.
In the absence of hyperuricemia-specific medication
there was even a direct link from UA to exacerbations,
probably due to the fact that untreated patients had
higher uric acid levels (see Fig. 1). Overall, our results
were not critically dependent on the inclusion of pa-
tients with the diagnosis of hyperuricemia or the pres-
ence of specific mediation. The major role was played by
UA, strongly suggesting a causative role of UA itself for
clinically relevant outcomes in COPD.
The observed association of lung function with UA is
in line with previous results regarding FVC and FEV1 in
lung healthy subjects [9], or FEV1 in COPD patients [2].
In our study population we found both FVC and FEV1
to be linked to UA. In parallel to findings in patients
with pulmonary hypertension [21], we observed that
6-MWD was also linked to UA in patients with COPD.
Moreover, UA levels have been shown to be related to
exacerbations in patients with COPD [2], as well as
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Table 2 Results of the final path analysis model
Regression Estimate S.E. C.R. Standardized P
Uric acid ← BMI .079 .006 12.631 0.273 p < 0.001
Uric acid ← Packyears .052 .013 4.058 0.088 p < 0.001
Uric acid ← Age .019 .004 4.903 0.105 p < 0.001
CV comorbidity ← Uric acid .054 .015 3.674 0.083 p < 0.001
CV comorbidity ← Age .024 .003 9.235 0.201 p < 0.001
CV comorbidity ← BMI .033 .004 7.722 0.173 p < 0.001
FEV1 ← Age .306 .051 6.009 0.137 p < 0.001
FEV1 ← Uric acid −0.790 .284 −2.781 −0.065 0.005
FEV1 ← BMI .565 .083 6.813 0.160 p < 0.001
FEV1 ← CV comorbidity −1.294 .437 −2.963 −0.069 0.003
Exacerbations ← FEV1 −.006 .001 −10.937 −0.240 p < 0.001
Exacerbations ← CV comorbidity .033 .011 3.067 0.067 0.002
6-MWD ← Uric acid −6.090 1.376 −4.425 −0.087 p < 0.001
6-MWD ← FEV1 2.573 .113 22.856 0.448 p < 0.001
6-MWD ← Age −3.025 .249 −12.168 −0.236 p < 0.001
6-MWD ← BMI −3.816 .406 −9.402 −0.187 p < 0.001
6-MWD ← Exacerbations −22.530 4.276 −5.268 −0.102 p < 0.001
6-MWD ← CV comorbidity −7.578 2.120 −3.575 −0.070 p < 0.001
Covariances Estimate S.E. C.R. Standardized P
Age ↔ Packyears 1.152 .475 2.428 0.055 p < 0.015
BMI ↔ Packyears 1.539 .302 5.102 0.116 p < 0.001
The upper panel refers to the directed arrows (regression terms) depicted in Figs. 2 and 3, whereby the left part lists the arrows shown in these figures. The right
part shows the results of the corresponding statistical tests. The first column of the right part shows the non-standardized estimate of the respective regression
coefficient, the second column the standard error (S.E.) of this coefficient, the third column the ratio of these two values (critical ratio, C.R.) which is used for
significance testing. The forth column shows the standardized estimates of the regression coefficients shown in the first column. The last column shows the
significance level based on the generalized least squares (GLS) procedure of AMOS. In an analogous manner the lower panel shows the covariances (bidirectional
arrows in Figs 2 and 3) between risk factors, as well as the respective standard errors, critical ratios, correlation coefficients and significance levels
Fig. 2 Dependence on risk factors. All variables were adjusted for gender, except for exacerbations and all shown relationships were statistically
significant (p < 0.05 each). The arched arrows indicate the correlations between predictors. The error terms of the dependent variables have been
omitted for the sake of clarity
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cardiovascular comorbidities [22]. Both findings were
confirmed by our data which therefore are fully compat-
ible with the known link between UA and mortality [1].
UA levels are known to be influenced by a variety of fac-
tors, among them overweight, age and male gender. These
risk factors were also significant predictors in our data. In
the path analysis gender was implicit and taken into ac-
count by the use of appropriately adjusted values. As ex-
cretion rate has an effect on UA levels [9], we tentatively
also included creatinine as a biomarker in additional ana-
lyses. Importantly, this did not lead to a change of the role
played by UA in our network. Higher values of BMI were
associated with higher values of FEV1, which is a common
finding in COPD [19]. At the same time, there were asso-
ciated with higher levels of UA, however UA itself had a
negative effect on FEV1, pointing towards greater airflow
limitation. Taken together, this observation again under-
lines that UA itself has effects that are explained by com-
mon risk factors like BMI.
Thus, patients with hyperuricemia showed different
ranges of UA depending on the presence of specific
medication as illustrated in Fig. 1. The associations iden-
tified by path analysis became even stronger when ex-
cluding patients with specific medication. Remarkably,
most of the previous studies investigated the role of UA
in COPD irrespective of a diagnosis of hyperuricemia.
As there were no major differences when including or
excluding these patients, our data support this approach.
The most important factor seemed to be the level of UA
not the diagnosis. On the other hand, our observations re-
garding the additional link between UA and exacerbations
indicate that the presence of hyperuricemia-specific medi-
cation can modulate the results, suggesting that future
analyses should take account of diagnosis, medication and
biomarker. As a secondary finding, Fig. 1 demonstrates
the effectiveness of hyperuricemia-specific therapy in our
study population but also shows that UA levels were still
higher than in patients without the diagnosis of
hyperuricemia.
Beyond lung function and physical capacity, the rate
and severity of exacerbations are determinants of the
prognosis in COPD [12, 23]. We coded exacerbations
through a binary variable equivalent to the difference be-
tween the AB and CD groups in the recent GOLD rec-
ommendations [15]. This was motivated by the aim to
use a definition close to that established for therapeutical
decisions. Exacerbations defined in this way were
dependent on lung function and by themselves had a
negative effect on 6-MWD, in accordance with previous
data [24, 25]. The link to 6-MWD appears plausible
since exacerbations often lead to an irreversible deterior-
ation of clinical state. Despite the indirect effects of UA
mediated via both exacerbations and FEV1, it was also
directly associated with 6-MWD. We do not know
whether this could be partially due persistent motoric
impairment from gout arthritis even in the absence of
acute episodes.
In the path analysis model exacerbations were
dependent on FEV1. The independent effect of UA on
exacerbations was statistically significant only when ex-
cluding patients with hyperuricemia-specific medication.
This seems understandable due to the reduction in the
range of variation of UA compared to patients with hy-
peruricemia without specific UA-lowering medication.
These observations support the hypothesis that UA in-
fluences the risk/severity of COPD exacerbations. Taking
into account the different paths linking UA to exacerba-
tions, our findings suggested that an increase in UA level
by 2 mg/dl was linked to a shift by about 5% from the
low to the high exacerbation category. A potential
pathophysiological link could be endothelin-1 which is
known to be elevated in hyperuricemia, but also in
asthma and COPD exacerbations [5]. Furthermore,
pro-inflammatory effects of UA in terms of TNF-alpha
activation have been described [26]. The associations of
the cardiovascular comorbidity count with UA but also
functional measures and exacerbations suggest that UA
triggers pro-inflammatory processes that are relevant for
Fig. 3 Relationship between all other variables except risk factors. All variables were adjusted for gender, except for exacerbations and all shown
relationships were statistically significant (p < 0.05 each). The arched arrows indicate the correlations between predictors. The error terms of the
dependent variables have been omitted for the sake of clarity
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cardiovascular diseases [22] which in turn have an im-
pact on COPD prognosis [27]. Taken together, it might
well be that UA exerts part of its effects on functional
state and mortality of COPD via a set of inflammatory
compounds.
Limitations and strength
Obvious limitations of the study are its cross-sectional
and non-interventional design. Furthermore, we did not
have data on the history of clinical manifestations of
gout, in terms of acute episodes. Patients with the
physician-based diagnosis of hyperuricemia are poten-
tially more health-conscious and may therefore have a
better physical capacity and prognosis, which could in-
fluence our results. Moreover, there was no information
on the specific medical reasons why patients received
hyperuricemia-specific treatment. Also, there was no in-
formation on the duration of the hyperuricemia-specific
treatment. This, however, appeared to be of minor im-
portance, since the major results were independent of
excluding or including these patients. Long-term
follow-up data could reveal whether the relationships
observed in a cross-sectional analysis are also reflected
in the relationships between the changes of parameters
within the follow-up period. The strength of our study
was its large sample size which allowed the use of so-
phisticated statistical methods with the aim to disentan-
gle the role of UA from other influencing factors.
Moreover we could rely on comprehensive, high quality
data of lung function and patients’ clinical
characteristics.
Conclusion
Within the limits of a cross-sectional approach, our
results strongly suggest that uric acid is not only a
useful biomarker for single entities in COPD but also
plays a central role in this disease. It is simultan-
eously associated with determinants of worse COPD
prognosis including airway obstruction, cardiovascular
comorbidities, exacerbations and physical capacity, ir-
respective of common risk factors. This suggests that
more attention should be paid to the levels of uric
acid in the evaluation of COPD disease status. The
described role of uric acid should be substantiated in
future targeted intervention trials.
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